These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27329820)

  • 1. Integrated genetic and pharmacologic interrogation of rare cancers.
    Hong AL; Tseng YY; Cowley GS; Jonas O; Cheah JH; Kynnap BD; Doshi MB; Oh C; Meyer SC; Church AJ; Gill S; Bielski CM; Keskula P; Imamovic A; Howell S; Kryukov GV; Clemons PA; Tsherniak A; Vazquez F; Crompton BD; Shamji AF; Rodriguez-Galindo C; Janeway KA; Roberts CW; Stegmaier K; van Hummelen P; Cima MJ; Langer RS; Garraway LA; Schreiber SL; Root DE; Hahn WC; Boehm JS
    Nat Commun; 2016 Jun; 7():11987. PubMed ID: 27329820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin.
    Nair JS; Musi E; Schwartz GK
    Clin Cancer Res; 2017 Aug; 23(15):4301-4311. PubMed ID: 28314790
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
    Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D; Kynnap BD; Christie AL; Yang X; Cowley GS; Leeper BA; Morton CL; Dwivedi B; Lawrence T; Rupji M; Keskula P; Meyer S; Clinton CM; Bhasin M; Crompton BD; Tseng YY; Boehm JS; Ligon KL; Root DE; Murphy AJ; Weinstock DM; Gokhale PC; Spangle JM; Rivera MN; Mullen EA; Stegmaier K; Goldsmith KC; Hahn WC; Hong AL
    Commun Biol; 2024 Apr; 7(1):426. PubMed ID: 38589567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
    Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
    Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 6. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
    Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
    Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
    Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
    Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
    Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
    Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal medullary carcinomas depend upon
    Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
    Elife; 2019 Mar; 8():. PubMed ID: 30860482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
    Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
    Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 15. [Radiation response enhanced by inhibition of XPO1 in preclinical rectal cancer models].
    von Fallois M; Depping R
    Strahlenther Onkol; 2016 Dec; 192(12):961-962. PubMed ID: 27757501
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
    von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
    Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S
    Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
    Dela Cruz FS; Diolaiti D; Turk AT; Rainey AR; Ambesi-Impiombato A; Andrews SJ; Mansukhani MM; Nagy PL; Alvarez MJ; Califano A; Forouhar F; Modzelewski B; Mitchell CM; Yamashiro DJ; Marks LJ; Glade Bender JL; Kung AL
    Genome Med; 2016 Oct; 8(1):116. PubMed ID: 27799065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.